Jardiance Patent Protection
15 patents · Boehringer Ingelheim
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 7713938 | Drug substance & product patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 15, 2027 | 1.3y left |
| 7579449 | Drug substance (composition of matter) patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Feb 1, 2029 | 2.6y left |
| 8551957 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Apr 14, 2030 | 3.8y left |
| 12115179 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Aug 11, 2030 | 4.1y left |
| 12527810 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 22, 2033 | 7.3y left |
| 12263153 | Orange Book listed patent | Boehringer Ingelheim | Apr 3, 2034 | 7.8y left |
| 12427162 | Orange Book listed patent | Boehringer Ingelheim | Apr 3, 2034 | 7.8y left |
| 11666590 | Orange Book listed patent | Boehringer Ingelheim | Apr 3, 2034 | 7.8y left |
| 10258637 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 3, 2034 | 8.3y left |
| 11090323 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 3, 2034 | 8.3y left |
| 12433906 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 3, 2034 | 8.3y left |
| 11833166 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 3, 2034 | 8.3y left |
| 11813275 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Oct 3, 2034 | 8.3y left |
| 9949997 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Nov 17, 2034 | 8.4y left |
| 9949998 | Orange Book listed patent (incl. pediatric exclusivity extension) | Boehringer Ingelheim | Dec 11, 2034 | 8.5y left |
Related Drug Patent Expirations
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
6 patents · earliest expires 2027 · Novartis AG
3 patents · earliest expires 2027 · Pfizer Inc.
44 patents · earliest expires 2027 · Pharmacyclics LLC
12 patents · earliest expires 2027 · AstraZeneca AB
2 patents · earliest expires 2027 · Celgene Corporation
Jardiance is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Jardiance’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.